EcoDrugPlus

Notch Receptor 1

Ensembl ID : ENSBTAG00000022799
Gene Symbol: NOTCH1
5 Cross references
279 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSBTAG00000043971
Gene Symbol: NOTCH3
5 Cross references
212 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSBTAG00000020270
Gene Symbol: NFKB1
54 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSBTAG00000006017
Gene Symbol: NFKB2
43 Enzyme and pathways 5 Cross references
136 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSBTAG00000003264
Gene Symbol: NR1H2
18 Enzyme and pathways 5 Cross references
315 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSBTAG00000010681
Gene Symbol: NR1H3
18 Enzyme and pathways 5 Cross references
404 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSBTAG00000013596
Gene Symbol: NR1H4
21 Enzyme and pathways 5 Cross references
400 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSBTAG00000019472
Gene Symbol: NR3C1
12 Enzyme and pathways 5 Cross references
292 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSBTAG00000027182
Gene Symbol: NR3C2
12 Enzyme and pathways 5 Cross references
226 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSBTAG00000020936
Gene Symbol: NOD2
30 Enzyme and pathways 5 Cross references
179 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSBTAG00000003202
Gene Symbol: OPRD1
7 Enzyme and pathways 5 Cross references
266 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSBTAG00000000914
Gene Symbol: OPRK1
7 Enzyme and pathways 5 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).